We are live on ! Find out more
RGN

REGENERX BIOPHARMACEUTICALS
RGN

Delisted

RGN was delisted on the 22nd of December, 2010.

Back to rankings

2 hedge funds and large institutions have $89K invested in REGENERX BIOPHARMACEUTICALS in 2020 Q3 according to their latest regulatory filings, with funds opening new positions, increasing their positions, reducing their positions, and 0 closing their positions.

New
Increased
Maintained
Reduced
Closed

27% more capital invested

Capital invested by funds: $70K → $89K (+$19K)

0% more funds holding

Funds holding: 2 → 2 (0)

Holders
2
Holders Change
–
Holders Change %
0%
% of All Funds
0.04%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
–
Increased
–
Reduced
–
Closed
–
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

No buyers this quarter

Top Sellers

No sellers this quarter

RGN Hedge Fund Activity: Q3 2020 in Review

2 of the 4,970 institutional investors tracked by Wall St. Rank reported a position in REGENERX BIOPHARMACEUTICALS (RGN) for Q3 2020, worth a combined $89K — up 27% from $70K a quarter earlier.

Fund positioning in RGN was balanced in Q3 2020: 0 funds opened new positions, 0 closed out, 0 added to existing stakes and 0 trimmed.

  • 2 institutional investors held REGENERX BIOPHARMACEUTICALS (RGN) as of Q3 2020, unchanged from Q2 2020.
  • Funds reported $89K of REGENERX BIOPHARMACEUTICALS stock for Q3 2020, up 27% quarter-over-quarter.
  • 0 funds opened new REGENERX BIOPHARMACEUTICALS positions in Q3 2020 and 0 closed out.

Based on aggregated 13F filings for Q3 2020.